Posts Tagged: pharmaceuticals


Waiving IP Rights During Times of COVID: A ‘False Good Idea’

Over the course of four months, close to 850 million doses of COVID-19 vaccines have been administered in over 100 countries. To the extent the unprecedented pace of research, …
By Hans Sauer
2 months ago 1

Bills to Lower Prescription Drug Costs and Boost Biosimilars Sent to Biden’s Desk

The U.S. House of Representatives yesterday approved two bills meant to lower prescription drug prices and sent them on to President Joe Biden for approval. The …
By Eileen McDermott
2 months ago 1

Industry Comments on Proposed Changes to Bayh-Dole Regulations Zero in on March-In Language

On January 12, the National Institute of Standards and Technology (NIST) published a request for comments on proposed changes to regulations that support the University and Small Business …
By Gene Quinn
2 months ago 0

Pfizer Rejects Accusations it Infringed COVID-19 Vaccine Assay Technology

Pfizer and BioNTech have hit back at Allele Biotechnology and Pharmaceuticals, Inc.’s October 2020 complaint accusing the COVID-19 vaccine manufacturers of infringing Allele’s U.S. patent …
By La'Cee Conley
4 months ago 1

Should the Biden Administration Look to Pharma for New USPTO Director?

The United States is not even two weeks into the administration of President Joe Biden and it’s likely that the administration’s selection for Director of …
By Steve Brachmann
5 months ago 7

Calls for WTO to Suspend IP Rights for Vaccine Innovation Would Jeopardize Incredible Progress

The biggest vaccination effort in the history of medicine is underway to eradicate the global pandemic, with several strong prospects appearing poised for regulatory approval. As of …
By Patrick Kilbride
6 months ago 10

A Misguided Op-Ed, a Key Report, and Why Holding the U.S. Lead in the Life Sciences is More Important Than Ever

Our current experiences with COVID-19 in the United States, together with headlines warning of major efforts by the Chinese and Russian governments to hack corporate, academic and …
By Joseph Allen
11 months ago 6

IP Valuation for the Preservation of Public Health: Managing IP in the Age of COVID-19

Certainly, patents that read on a potential cure for COVID-19 deserve special treatment. After all, the cure for COVID-19 is not only crucial to save lives all …
By Roya Ghafele
12 months ago 0

WHO’s C-TAP Initiative Pushes for Non-Exclusive Global Licensing Amid Pharma Industry Concerns

On Friday, May 29, the World Health Organization (WHO) officially launched the COVID-19 Technology Access Pool (C-TAP), an initiative which is intended to improve access to treatments, vaccines …
By Steve Brachmann
1 year ago 2

Efforts to Villainize Biotech, Pharma over COVID-19 are Political Theater and Opportunism

If the objective is to beat this virus as fast as possible it simply isn’t helpful to talk about the compulsory licensing of drugs that don’…
By Gene Quinn
1 year ago 11

Innovators Rush to Solve Coronavirus Pandemic While Countries Contemplate Compulsory Licensing

Since China announced the first fatality caused by a virus about which little was known at the time, coronavirus and the disease it causes, COVID-19, has grown …
By Steve Brachmann
1 year ago 2

We Won’t Stop Coronavirus Without IP

The recent White House meeting with leaders from American pharmaceutical companies sought their help in solving the coronavirus that originated in Wuhan, China and is currently gripping …
By James Edwards
1 year ago 16

Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’

A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two important …

State Pharmaceutical Importation Programs Threaten Patients and Innovation

In mid-December, President Trump presented a plan to lower prescription drug prices by allowing states, drug wholesalers and pharmacies to import some cheaper drugs from Canada. While …

The Fifth Circuit Must Preserve the Patent-Antitrust Balance by Upholding Actavis

The pharmaceutical industry presents some of the most important and challenging issues lying at the intersection of the patent and antitrust laws. On the one hand, patents …
By Michael Carrier
2 years ago 0